Notably, after treatment with lenabasum (a CB2R antagonist), the infiltration of CD4+ T lymphocytes, as well as the expression of CB2R, IL-31, IFN-γ, and IFN-β were all downregulated in the skin lesions, but this phenomenon was not observed in the PBMCs of DM patients (9). The gene discussed is CD4; the disease is dermatomyositis.